Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019: Acalabrutinib shows remarkable benefit in relapsed or refractory chronic lymphocytic leukaemia

The Phase III ASCEND study of the Bruton’s Tyrosine Kinase inhibitor (BTKi) acalabrutinib in relapsed or refractory chronic lymphocytic leukaemia (CLL) has been presented at the 2019 European Hematology Association (EHA) Annual Meeting.

The study tested acalabrutinib versus rituximab with idelalisib (IdR) or bendamustine (BR), commonly used CLL regimens.

BRK inhibition is a well-established therapeutic approach in CLL.

Acalabrutinib is a highly selective, potent inhibitor of BTK that has previously demonstrated substantial activity and improved tolerability in patients with CLL.

In this study, acalabrutinib monotherapy significantly improved progression-free survival (PFS), with a more tolerable safety profile, compared with IdR/BR in patients with relapsed or refractory CLL, reducing the risk of disease progression or death by 69% after 16.1 months.

At 12 months, 88% of patients on acalabrutinib showed no disease progression compared to 68% for the control arm, with tolerability consistent with the known profile.

These results are significant because there is a need for an effective but also well-tolerated BTKi for patients with CLL.

The ASCEND study results indicate that acalabrutinib has the potential to change current practice by providing a well-tolerated, highly effective BTKi treatment option.

Source: EHA



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation